ClinicalTrials.gg

Program

asciminib

Also written as “Asciminib”, “Asciminib single agent” and “ABL001”.

Its studies are mostly in Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Leukemia, Myeloid, Chronic-Phase · Bronchiolitis Obliterans Syndrome · Renal Insufficiency, led by Novartis.

Furthest: phase 4, since May 4, 202116 company-led studies, 7 open or runningNext primary completion: Sep 3, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis167 open or runningphase 4since May 4, 2021Feb 28, 2014Sep 3, 2027phase 2 · NCT04925479

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Feb 28, 2014.

  1. Apr 27, 2016Phase 1 study in Hepatic ImpairmentNCT02857868 · 32 enrolled · United States
  2. Mar 9, 2017Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03106779 · 233 enrolled · United States, Argentina, Australia and more
  3. Jun 15, 2018Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT03578367 · 104 enrolled · United States, Austria, Canada and more
  4. Jul 20, 2018Phase 1 study in Renal InsufficiencyNCT03605277 · 14 enrolled · Bulgaria, Germany
  5. Dec 7, 2020Phase 3 study in Leukemia, Myeloid, Chronic-PhaseNCT04666259 · 56 enrolled · United States
  6. Mar 10, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04795427 · 84 enrolled · China
  7. May 4, 2021Phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522 · 347 planned · United States, Argentina, Austria and more
  8. May 18, 2021Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479 · 46 enrolled · United States, China, France and more
  9. Jun 8, 20212 phase 3 studies in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04971226, NCT04948333
  10. May 17, 2022Phase 2 study in Leukemia, Myeloid, Chronic-PhaseNCT05384587 · 34 enrolled · United States
  11. Jul 11, 2022Phase 3 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT05456191 · 568 enrolled · United States, Argentina, Bulgaria and more
  12. May 20, 2024Phase 4 study in Bronchiolitis Obliterans SyndromeNCT06427811 · 85 enrolled · India
  13. Jul 17, 2024Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534 · 20 planned · France
  14. Jan 15, 2026Phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074 · 50 planned · United States, Australia, Brazil and more

Ahead

  1. Sep 3, 2027Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04925479
  2. Feb 17, 2029Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT06514534
  3. Aug 30, 2030Primary completion: phase 4 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT04877522
  4. Feb 23, 2033Primary completion: phase 2 study in Leukemia, Myelogenous, Chronic, BCR-ABL PositiveNCT07354074

TargetBeta

ABL1 →BCR →read by rule
“Tyrosine-protein kinase ABL inhibitor; Bcr/Abl fusion protein inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
nilotinibruleNovartisphase 457
olverembatinibruleAscentage Pharma Group Internationalphase 310
EmbibatinibHansoh Pharmaceutical Groupphase 37
TQB3911Sino Biopharmaceuticalphase 11

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07354074Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Brazil and more2RecruitingFeb 23, 203350
NCT06514534Leukemia, Myelogenous, Chronic, BCR-ABL Positive · France2RecruitingFeb 17, 202920
NCT06427811Bronchiolitis Obliterans Syndrome · India4CompletedMar 18, 202685
NCT05456191Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Bulgaria and more3Active, not recruitingMay 15, 2025568
NCT05384587Leukemia, Myeloid, Chronic-Phase · United States2Active, not recruitingAug 13, 202534
NCT04948333Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Argentina, Austria, Brazil and more3CompletedMar 12, 2024199
NCT04971226Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, Austria and more3Active, not recruitingNov 28, 2023405
NCT04925479Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, China, France and more2Active, not recruitingSep 3, 202746
NCT04877522Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Austria and more4RecruitingAug 30, 2030347
NCT04795427Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China2CompletedMay 29, 202384
NCT04666259Leukemia, Myeloid, Chronic-Phase · United States3CompletedJun 20, 202356
NCT03605277Renal Insufficiency · Bulgaria, Germany1CompletedMar 18, 201914
NCT03578367Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Austria, Canada and more2CompletedNov 8, 2021104
NCT03106779Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Argentina, Australia and more3CompletedMay 25, 2020233
NCT02857868Hepatic Impairment · United States1CompletedJul 20, 201732
NCT02081378Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States, Australia, France and more1CompletedJun 3, 2021326

How it is read

Names in the registry

  • “Asciminib”, 5 entries
  • “Asciminib single agent”, 2 entries
  • “ABL001”, 2 entries
  • “asciminib”, 2 entries
  • “Asciminib single agent pediatric formulation”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.